Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place.
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
17
8
2020
medline:
3
11
2020
entrez:
16
8
2020
Statut:
ppublish
Résumé
Thiopurines have been widely used to maintain steroid-free remission in children with inflammatory bowel disease (IBD). However, within the expanding treatment armamentarium, the role of these non-selective immunomodulators has been questioned, especially in pediatric patients, who often present with a more aggressive disease course, which can impact growth and development. The less favorable safety but also inferior efficacy profile associated with thiopurines, in contrast to the newer biological therapies, has interfered with their use. The future place of thiopurines in the management of childhood IBD, therefore, needs revisiting. This review provides a practical overview on the historical and current use of thiopurines in pediatric IBD with specific attention for thiopurine S-methyltransferase testing and monitoring of thiopurine metabolite levels as an approach to improve outcomes. We also give a personal expert opinion on the future role of these drugs in childhood IBD.
Identifiants
pubmed: 32797366
doi: 10.1007/s40272-020-00411-5
pii: 10.1007/s40272-020-00411-5
doi:
Substances chimiques
Biological Products
0
Immunologic Factors
0
Purines
0
Thionucleosides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM